Aviva plc (AIVAF)
| Market Cap | 28.59B +7.6% |
| Revenue (ttm) | 38.60B +26.1% |
| Net Income | 1.03B +35.3% |
| EPS | 0.36 +13.7% |
| Shares Out | n/a |
| PE Ratio | 27.70 |
| Forward PE | 11.63 |
| Dividend | 0.53 (6.02%) |
| Ex-Dividend Date | Mar 26, 2026 |
| Volume | 250 |
| Open | 8.76 |
| Previous Close | 8.76 |
| Day's Range | 8.45 - 8.76 |
| 52-Week Range | 8.00 - 9.32 |
| Beta | 0.62 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 14, 2026 |
About Aviva
Aviva plc provides various insurance, retirement, and wealth products in the United Kingdom, Ireland, Canada, India, and China. It operates through General Insurance; Insurance, Wealth & Retirement; Aviva Investors; and International Investments segments. The company offers gadget, home, motor, pet, and health insurance, as well as commercial, specialty insurance and protection. It also provides life insurance, long-term health and accident insurance, savings, pension, and annuity products, as well as pension fund and lifetime mortgage products... [Read more]
Financial Performance
In 2025, Aviva's revenue was 28.68 billion, an increase of 26.11% compared to the previous year's 22.74 billion. Earnings were 767.00 million, an increase of 21.17%.
Financial numbers in GBP Financial StatementsNews
UK's Aviva takes full ownership of India unit after New Delhi eases foreign investment rules
British insurer Aviva said on Thursday it had agreed to buy the remaining 26% stake in its Indian life insurance joint venture from local partner Dabur Invest Corp, taking full ownership of the bu...
Aviva price target raised to 680 GBp from 670 GBp at Morgan Stanley
Morgan Stanley raised the firm’s price target on Aviva (AIVAF) to 680 GBp from 670 GBp and keeps an Equal Weight rating on the shares.
Aviva detects record £230m in bogus insurance claims as use of AI rises
Insurer found 18,400 suspect claims last year with some scammers using AI to fake accident scenes and documents
Aviva price target lowered to 715 GBp from 725 GBp at JPMorgan
JPMorgan lowered the firm’s price target on Aviva (AIVAF) to 715 GBp from 725 GBp and keeps a Neutral rating on the shares.
Aviva initiated with a Buy at Berenberg
Berenberg initiated coverage of Aviva (AIVAF) with a Buy rating and 800 GBp price target The insurer is among the few scale players capturing the “growing pool” of UK retirement…
Aviva Earnings Call Transcript: Q1 2026
Strong Q1 growth with general insurance premiums up 19% and Wealth net flows up 49% year-over-year. Direct Line integration is on track, with improved profitability and capital synergies expected by year-end. Solvency remains robust at 171%.
Aviva Earnings release: Q1 2026
Aviva released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Aviva Posts Rise in Insurance Premiums
The insurer and asset manager's quarterly general insurance premiums reached £3.4 billion, up 19% compared with a year prior.
Aviva downgraded to Hold from Buy at Jefferies
Jefferies downgraded Aviva (AIVAF) to Hold from Buy with a price target of 637 GBp, up from 560 GBp. The firm sees a balanced risk/reward at current share levels with…
Aviva price target raised to 765 GBp from 760 GBp at Deutsche Bank
Deutsche Bank analyst Kailesh Mistry raised the firm’s price target on Aviva (AIVAF) to 765 GBp from 760 GBp and keeps a Buy rating on the shares. Published first on…
Aviva Earnings Call Transcript: Q4 2025
Delivered strong growth with operating profit up 25%, EPS at 56p, and a 10% dividend increase. Achieved 2026 targets early, raised ambitions, and advanced Direct Line integration, with robust performance across all segments and continued investment in AI and efficiency.
Aviva Annual report: Q4 2025
Aviva has published its Q4 2025 annual report on March 5, 2026.
Aviva Annual report: Q4 2025
Aviva has published its Q4 2025 annual report on March 5, 2026.
Aviva Slides: Q4 2025
Aviva has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 5, 2026.
Aviva Bio Announces FDA Guidance on Development Pathway for Women's Testosterone Therapy and New Evidence of a Reduced Risk of Breast Cancer Cell Proliferation for AVA-291
CONCORD, Mass.--(BUSINESS WIRE)--Aviva Bio received FDA guidance on women's testosterone and reported new data showing AVA-291's markedly reduced breast cancer cell proliferation.
Aviva downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst Hadley Cohen downgraded Aviva (AIVAF) to Equal Weight from Overweight with a price target of 670 GBp, down from 690 GBp. The firm adjusted ratings in European…
Aviva resumed with a Buy at Deutsche Bank
Deutsche Bank analyst Kailesh Mistry resumed coverage of Aviva (AIVAF) with a Buy rating and 760 GBp price target
Aviva downgraded to Neutral from Overweight at JPMorgan
JPMorgan downgraded Aviva (AIVAF) to Neutral from Overweight with an unchanged price target of 725 GBp. The firm adjusted ratings in the European insurance space as part of its 2026…
Aviva Earnings Call Transcript: Q3 2025
Q3 saw double-digit profit growth, improved combined ratios, and strong capital generation. New three-year targets include 11% EPS CAGR, >20% ROE by 2028, and over GBP 7 billion in cash remittances, with Direct Line integration driving higher cost and capital synergies.
Aviva Earnings release: Q3 2025
Aviva released its Q3 2025 earnings on November 13, 2025, summarizing the period's financial results.
Aviva Slides: Q3 2025
Aviva has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 13, 2025.
Here's why the Aviva share price is pumping and what next?
The Aviva share price continued its strong rally this week, reaching its highest level since 2008 as the turnaround efforts by Amanda Blanc and its recent prices increase paid off.
Aviva shares hit 17-year high as profits surge 22% — can the rally last?
Aviva shares climbed to their highest level since before the 2008 financial crisis on Thursday, after the FTSE 100 insurer reported a 22% jump in first-half operating profit and lifted its interim div...
Aviva Earnings Call Transcript: H1 2025
First-half 2025 saw strong growth in profit, capital, and customer metrics, with operating profit up 22% and a 10% dividend increase. The Direct Line acquisition is progressing well, supporting further growth and capital synergies.
Aviva Quarterly report: H1 2025
Aviva has published its H1 2025 quarterly earnings report on August 14, 2025.